US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redsense Medical announces strong closing of Q4 with net sales around 12,7 mSEK

Redsense Medical is pleased to announce a strong closing to the fourth quarter with net sales amounting to 12,7 mSEK and an indicative profit of 5,6 mSEK; This would bring net sales for full year 2024 up to around 28 mSEK. The strong finish is driven by a partial Q3 order delivered in the first week of October as well as further fullfillment deliveries per the quarterly reviews we started with US distribution partners in June 2024. “The final result is yet to be determined, but with this strong finish we are optimistic about where we will land and look forward to sharing the full picture

Redsense Medical announces completion of Clamp usability testing

Redsense Medical announces the completion of the usability testing phase with the Redsense Clamp, entering the final stage towards CE marking. A study was conducted with Canadian home dialysis patients that used the Redsense blood leakage alarm together with the Redsense Clamp, under supervision of Dr. Christopher Chan, Director of Division of Nephrology and Medical Director at the University Health Network in Toronto, Canada. The results of the study will be published in a scientific article. The next step is to finalize a usability report, to be reviewed by a Quality Assurance Provider,

Interim Report Q3 – January – September, 2024 Redsense Medical AB (publ.)

July – September 2024 · Net sales amounted to kSEK 5,030 (5,287). · Operating loss, EBIT amounted to kSEK -3,273 (-959). · Result after tax amounted to kSEK -3,271 (-1,008). · Earnings per share were SEK -1.99 (-0.07). · Other operating income/loss kSEK -1358 (260). Significant events during the period · On July 15, Redsense announced that ShapeQ GmbH after the second directed issue has passed the 25% threshold. · On Sept 16, Redsense announced that chairman of the board resigns, and a new acting chairman is appointed. · On Sept 21, Redsense

Redsense Medical to focus on core growth areas, discontinuing trading on OTCQX

Redsense Medical AB has decided not to renew its agreement with OTC Markets Group after the current term, which ends on December 31, 2024. Redsense Medical began trading on the OTCQX platform on September 29, 2023 under the symbol “RDSNF”. "While our time on the OTCQX platform has provided valuable insights, we have chosen to refocus our efforts toward key priotities that will better support our growth. Our primary goal is to accelarate profitability, and we believe the most effective use of our resources will be to drive sales growth and enhance communication with our strong and engaged

Nomination committee appointed for the 2025 Annual General Meeting in Redsense Medical AB

A nomination committee has been established ahead of the 2025 annual general meeting in Redsense Medical AB (publ). The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting May 8, 2024, consists of: Johannes Köpple, appointed by ShapeQ GmbH Susanne Olauson, appointed by Seventh Sense Adventures Holding AB Oscar Bergman, appointed by Swedbank Robur Fonder Susanne Olauson, the chairman of the board is convening The nomination committee's task is to submit proposals to the annual general meeting regarding;

Redsense Medical AB (publ) appoints a new CEO

Redsense Medical AB is pleased to announce that Sebastien Bollue takes over as the company's new CEO as of October 1[st], 2024.  Sebastien Bollue has long and solid experience of eight years within the company and worked closely with the company's founder, Patrik Byhmer. During his time at Redsense Medical AB, Sebastien Bollue has developed a deep understanding of both the company's internal needs and the dynamics of the market. His extensive background in production, sales, marketing and business development makes him suitable to lead the company into the next phase of growth. During

Chairman of the board of Redsense Medical AB resigns - Acting chairman of the board appointed

Redsense Medical AB (publ), a leader in innovations for safety and monitoring of the vein needle in dialysis treatment, announces that board chairman Eva Walde has chosen to leave her post due to personal reasons. The board has unanimously decided to appoint board member Susanne Olauson as acting board chairman until the next ordinary general meeting, when a permanent successor will be elected. The company thanks Eva Walde for her efforts during her time as chairman and wishes her every success in her future undertakings.

Interim Report Q2 – January – June, 2024 Redsense Medical AB (publ.)

April – June 2024 · Net sales amounted to kSEK 8,749 (4,831) · Operating profit, EBIT amounted to kSEK 613 (-3,045). · Result after tax amounted to kSEK 625 (2,966). · Earnings per share were SEK 0.04 (0.21). Significant events during the period · On April 24, The Board of Directors in Redsense resolved to carry out a directed share issue of approximately MSEK 9.8. · On May 22, Redsense announced that Discover Capital GmbH has sold all their shares in Redsense Medical AB (publ.) · On May 23, Redsense announced that ShapeQ GmbH has bought 750,000 shares

Major shareholding notification

Redsense Medical AB hereby announces that ShapeQ GmbH has passed the disclosure threshold of 25 percent shareholding. Through a recent directed issue, ShapeQ GmbH has acquired 1,000,000 shares which means a total holding of shares is 4,296,438 after the direct issue transaction, corresponding to approximately 26.1 percent of the votes and capital in Redsense Medical AB.   Contact information For more information, please contact: Jennie Kardell, CEOTelephone: +46 72-171 1264E-mail: jennie.kardell (at) redsensemedical.com Redsense Medical AB (publ), 556646-4862

Redsense has secured a new order worth MSEK 6.99

Redsense Medical has received a new order valued at MSEK 6.99 from one of its U.S. distributors This order reflects a step in our strategy to better align our sales with the needs of our end consumers. "We are glad to receive this new order and that we have been able to ship it all, in June, which underscores our dedication to operational excellence. We have an ambition to continue with this approach of getting more frequent orders to be able to further align our sales with the sales to the end consumers, this allows us to respond more effectively to market demands, " said Jennie Kardell,

The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of MSEK 7,5.

The Board of Directors in Redsense Medical AB (publ) ("Redsense" or the "Company") announces today that the Company’s Board of Directors, with the support from the authorization from the Annual General Meeting of 2024, has resolved on a directed cash issue of a maximum of 1,000,000 shares to ShapeQ GmbH at a subscription price of SEK 7,5 per share (the “Directed Issue”) Through the Directed Issue, the Company will receive a maximum of MSEK 7,5, before deduction of costs related to the issue. The Board of Directors has resolved that the Directed Issue of a maximum of 1,000,000 shares is

The CEO leaves Redsense Medical AB

The Board of Directors of Redsense Medical AB and Pontus Nobréus, CEO since Aug 2022, have reached a mutual agreement that Pontus Nobréus will leave his position as CEO. The board of Redsense has appointed the current CFO, Jennie Kardell, as acting CEO. The board would like to express its thanks to Pontus Nobréus for the two years he has led the company. Work on recruiting a new CEO will begin immediately. Redsense Medical AB The Board of Directors

Redsense Medical presents at Sedermeradagen Stockholm 2024

Sedermera Corporate Finance will once again host Sedermeradagen on May 22, 2024. The event will take place at Hotel At Six in Stockholm and offers the opportunity to get to know 16 highly interesting growth companies. Redsense Medical CEO Pontus Nobréus will present the company. The presentation will be held in Swedish. To register and for more information about the event: Sedermeradagen Stockholm 2024 - Sedermera Corporate Finance 

Redsense Medical Spotlight presentation at the 61[st] ERA Congress in Stockholm

Redsense Medical will exhibit at the 61[st] ERA (European Renal Association) Congress in Stockholm, May 23-26, 2024. The Redsense blood loss security systems will be showcased at booth F.320, including the upcoming Clamp that is expected to be commercially launched during 2024. The company was also allotted one of four Spotlight presentation slots, which is a novelty to this year’s programme and described as “Designed to showcase cutting-edge industry innovations and insights alongside scientific content”. Redsense has invited high-profile hemodialysis physicians Dr. Christopher Chan

Interim Report Q1 – January – March, 2024 Redsense Medical AB (publ.)

January – March 2024 · Net sales amounted to kSEK 1,711 (6,824)   · Operating loss, EBIT amounted to kSEK 2,656 (104).   · Result after tax amounted to kSEK -2,640 (413).   · Earnings per share were SEK -0.19 (0.03).   Significant events during the period · On January 8, Eva Walde was appointed new Chairman of the Board at Redsense Medical AB (publ.)   · On January 9, Redsense announced a change in the Nomination Committee for the 2024 Annual General Meeting.   · On February 6, the largest owner Seventh Sense Adventures Holdings AB

Redsense Medical welcomes new investment from ShapeQ to accelerate growth

Today Redsense Medical has announced a direct share issue to ShapeQ and the press release can be found at https://redsensemedical.com/investors-media/press-releases/. This direct share issue to ShapeQ, one of our current main investors, means that Redsense Medical will receive approximately MSEK 9.8 before deduction of costs related to the issue. It should be noted that subscription price exceeded the current market value. "The investment from ShapeQ is a clear sign of trust and commitment to drive Redsense towards a successful future. It is important to note that this investment is

The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of approximately MSEK 9,8.

The Board of Directors in Redsense Medical AB (publ) ("Redsense" or the "Company") announces today that the Company’s Board of Directors, with the support from the authorization from the Annual General Meeting of 2023, has resolved on a directed cash issue of a maximum of 1,404,081 shares to ShapeQ GmbH at a subscription price of SEK 7 per share (the “Directed Issue”) Through the Directed Issue, the Company will receive a maximum of approximately MSEK 9,8, before deduction of costs related to the issue.The Board of Directors has resolved that the Directed Issue of a maximum of 1,404,081

Redsense Medical attending Home Dialysis Congress in Germany

Redsense Medical will be participating and exhibiting at the 14th Cologne Home Dialysis Congress of the KfH. The event takes places April 26-27, 2024, in Cologne, Germany. The Congress is organized by KfH, the largest dialysis provider in Germany with 6 400 employees. As a non-profit organization, KfH provides dialysis to around 18 000 patients. KfH has recognized home dialysis as an important area to improve quality of care and life of dialysis patients. The Congress will offer the latest information and findings from Germany and abroad as well as practice-oriented lectures and

Home Dialysis Risk Prevention Act addressed in House Committee on Ways and Means Hearing

On March 12, 2024, the House Committee on Ways and Means Chairman Jason Smith (MO-08) held a Hearing to examine opportunities and challenges in enhancing access to care in patients´ home and modernizing care in rural and underserved communities. The Hearing was titled, “Enhancing Access to Care at Home in Rural and Underserved Communities.” and during the Hearing Rep. Adrian Smith (NE-03) made the following remarks: “Thank you to all our witnesses for joining us today to talk about this important topic. It is amazing to see how new technologies have expanded the boundaries of access

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe